Avenue Therapeutics

Avenue Therapeutics, Inc. is a specialty pharmaceutical company founded in 2015 and based in New York. The company focuses on acquiring, developing, and commercializing products primarily for use in acute and intensive care hospital settings. Its notable product candidate is intravenous Tramadol, which is currently in Phase III clinical trials aimed at treating moderate to moderately severe post-operative pain. Additionally, Avenue Therapeutics is developing therapies for various conditions, including AJ201 for spinal and bulbar muscular atrophy and BAER-101 for epilepsy and panic disorders. As of December 31, 2019, Avenue Therapeutics operates as a majority-controlled subsidiary of InvaGen Pharmaceuticals.